Benzinga Pro's Top 5 Stocks To Watch For Wednesday, December 14, 2022: FDX, MRNA, SOFI, DRI, DTC
|
|
Save time and jump to the most important pieces.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 11/19/2024 | $42.00 | Hold | Berenberg | |
| 11/18/2024 | $58.00 | Hold → Buy | HSBC Securities | |
| 11/15/2024 | $40.00 | Underperform | Wolfe Research | |
| 10/17/2024 | $55.00 | Mkt Perform | Bernstein | |
| 10/9/2024 | $301.00 | Buy | Citigroup | |
| 9/20/2024 | $300.00 | Buy → Hold | HSBC Securities | |
| 9/20/2024 | $334.00 → $328.00 | Buy | TD Cowen | |
| 9/20/2024 | $215.00 → $200.00 | Equal-Weight → Underweight | Morgan Stanley |
CAMBRIDGE, Mass., Nov. 20, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Metaphore Biotechnologies, a Flagship-founded biotechnology company designing novel therapeutics by combining machine learning and molecular mimicry, today announced that Angela Hwang, MBA, will join Flagship Pioneering as CEO-Partner, and Metaphore as Chief Executive Officer, effective January 1, 2025. Most recently, Hwang served as Chief Commercial Officer and President of the Global Biopharmaceuticals Business at Pfizer. During her tenure at Pfizer, Hwang helped brin
Williams was promoted from Operating Partner at Flagship Pioneering and President at Apriori Bio Apriori Bio has made significant progress in 2024, including securing a collaboration with CEPI, assembling a world class board of directors and building out an early pipeline of prospective vaccines CAMBRIDGE, Mass., Nov. 13, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Apriori Bio, a biotechnology company aimed at providing humanity with variant-resilient protection against rapidly-evolving viruses, today announced that Craig Williams, MBA, has been promoted to CEO-Partner at Flagship Pioneering and Chief Executive Officer of Apriori.
Valo Elevates Brett Blackman to Chief Operating Officer and Appoints Travis Wilson to its Board of Directors CAMBRIDGE, Mass., Nov. 13, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Valo Health today announced that industry leader Brian M. Alexander, M.D., M.P.H. has been appointed Chief Executive Officer of Valo Health and CEO-Partner of Flagship Pioneering. Dr. Alexander brings two decades of biotechnology, biopharma, and medical leadership, most recently as SVP, Research & Development and Head of Boston Roche Innovation Center (BRIC), for Roche/Genentech and previously as CEO of Foundation Medicine. Valo also announced the appointments of Brett Blackman
Berenberg initiated coverage of Moderna with a rating of Hold and set a new price target of $42.00
HSBC Securities upgraded Moderna from Hold to Buy and set a new price target of $58.00
Wolfe Research initiated coverage of Moderna with a rating of Underperform and set a new price target of $40.00
CAMBRIDGE, Mass., Nov. 20, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Metaphore Biotechnologies, a Flagship-founded biotechnology company designing novel therapeutics by combining machine learning and molecular mimicry, today announced that Angela Hwang, MBA, will join Flagship Pioneering as CEO-Partner, and Metaphore as Chief Executive Officer, effective January 1, 2025. Most recently, Hwang served as Chief Commercial Officer and President of the Global Biopharmaceuticals Business at Pfizer. During her tenure at Pfizer, Hwang helped brin
Ampersand's AND™ Platform will be used to identify programmed biologics for the treatment of obesity-related targets Montai's CONECTA™ AI platform will be used to identify small molecules directed to a potential Non-Small Cell Lung Cancer-related target Collaborations will leverage Pfizer's deep expertise in early discovery and development for cardiometabolic and cancer treatments, two priority therapeutic areas for the company CAMBRIDGE, Mass., Nov. 20, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced Ampersand Biomedicines and Montai Therapeutics have entered into agreements to identify targeted molecules that could potentially be further dev
ORLANDO, Fla., Nov. 19, 2024 /PRNewswire/ -- Darden Restaurants, Inc., (NYSE:DRI) plans to release its fiscal 2025 second quarter financial results before the market opens on Thursday, December 19, 2024, with a conference call to follow at 8:30 am ET. Rick Cardenas, CEO, and other senior management will discuss second quarter results and conduct a question and answer session. For those who cannot listen to the live broadcast, a replay will be available shortly after the call. What: Darden Restaurants, Inc. Fiscal 2025 Second Quarter Earnings Conference Call When: 8:30 am ET,
For Immediate Release: November 30, 2020 The U.S. Food and Drug Administration has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Dec. 17 to discuss the request for emergency use authorization (EUA) for a COVID-19 vaccine from Moderna, Inc. “In keeping with the FDA’s commitment to ensuring full transparency, dialogue and efficiency, the Vaccines and Related Biological Products Advisory Comm
4 - Solo Brands, Inc. (0001870600) (Issuer)
4 - SoFi Technologies, Inc. (0001818874) (Issuer)
4 - Solo Brands, Inc. (0001870600) (Issuer)
SC 13G/A - Solo Brands, Inc. (0001870600) (Subject)
SC 13G/A - Solo Brands, Inc. (0001870600) (Subject)
SC 13G/A - Moderna, Inc. (0001682852) (Subject)
ORLANDO, Fla., Nov. 19, 2024 /PRNewswire/ -- Darden Restaurants, Inc., (NYSE:DRI) plans to release its fiscal 2025 second quarter financial results before the market opens on Thursday, December 19, 2024, with a conference call to follow at 8:30 am ET. Rick Cardenas, CEO, and other senior management will discuss second quarter results and conduct a question and answer session. For those who cannot listen to the live broadcast, a replay will be available shortly after the call. What: Darden Restaurants, Inc. Fiscal 2025 Second Quarter Earnings Conference Call When: 8:30 am ET,
The Board of Directors of FedEx Corp. (NYSE:FDX) today declared a quarterly cash dividend of $1.38 per share on FedEx Corp. common stock, in line with the company's continued focus on delivering stockholder value. The dividend is payable January 3, 2025 to stockholders of record at the close of business on December 9, 2024. FedEx Corp. (NYSE:FDX) provides customers and businesses worldwide with a broad portfolio of transportation, e-commerce and business services. With annual revenue of $88 billion, the company offers integrated business solutions utilizing its flexible, efficient, and intelligent global network. Consistently ranked among the world's most admired and trusted employers, Fe
Reaffirms Full Year 2024 Guidance Solo Brands, Inc. (NYSE:DTC) ("Solo Brands" or "the Company") today announced its financial results for the three and nine month period ended September 30, 2024. "Our third quarter results were in line with our expectations despite a continued challenging macroeconomic backdrop for big ticket consumer durable items," said Chris Metz, Chief Executive Officer of Solo Brands. "We continue to see strong momentum and excitement from our retail partners; however, as expected, sales in our direct-to-consumer channel were challenged. During the quarter, we took decisive measures to address factors that were hindering our growth, and as a result of these actions,
10-Q - Solo Brands, Inc. (0001870600) (Filer)
10-Q - Moderna, Inc. (0001682852) (Filer)
8-K - Solo Brands, Inc. (0001870600) (Filer)
4 - SoFi Technologies, Inc. (0001818874) (Issuer)
4 - Solo Brands, Inc. (0001870600) (Issuer)
4 - Solo Brands, Inc. (0001870600) (Issuer)
Moderna (NASDAQ:MRNA) has outperformed the market over the past 5 years by 42.19% on an annualized basis producing an average annual return of 54.8%. Currently, Moderna has a market capitalization of $45.66 billion. Buying $1000 In MRNA: If an investor had bought $1000 of MRNA stock 5 years ago, it would be worth $8,701.97 today based on a price of $119.13 for MRNA at the time of writing. Moderna's Performance Over Last 5 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine and revie
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. Here's the list of options activity happening in today's session: Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume BSX PUT SWEEP BEARISH 08/16/24 $75.00 $68.9K 5.5K 2.1K MRNA CALL SWEEP NEUTRAL 11/15/24 $170.00 $121.
The Chinese government expressed its desire for U.S. firms to play a significant role in its economy after top U.S. executives engaged in a meeting with Chinese officials. What Happened: The delegation, led by FedEx Corporation (NYSE:FDX) CEO Raj Subramaniam, met with Chinese Vice-Premier He Lifeng and Foreign Minister Wang Yi. The visit aimed to gain first-hand insight following the conclusion of China’s third plenum, South China Morning Post reported on Tuesday. The Chinese officials expressed their hope that the U.S.-China Business Council could encourage American firms to seize opportunities in China, leading to mutual cooperation and development. Wang stated that the delegation’s